Source link : https://www.newshealth.biz/health-news/fda-approves-zanidatamab-for-biliary-tract-cancer/
The FDA on Wednesday granted accelerated approval to zanidatamab (Ziihera), a bispecific antibody, for pretreated HER2-positive biliary tract cancer. Approval stipulates use in unresectable or metastatic cases, with HER2 positivity defined as an immunohistochemistry (IHC) score of 3+. According to drugmaker Jazz Pharmaceuticals, the antibody binds to two extracellular sites on HER2, the first and […]
Author : News Health
Publish date : 2024-11-21 17:49:27
Copyright for syndicated content belongs to the linked Source.
inHealth